Investigation of the effect of GLP-1 and left ventricular function during myocardial ischaemia
| ISRCTN | ISRCTN69686930 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN69686930 |
| Secondary identifying numbers | 6562 |
- Submission date
- 19/05/2010
- Registration date
- 19/05/2010
- Last edited
- 11/08/2015
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Circulatory System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr Davis Dutka
Scientific
Scientific
University of Cambridge
Addenbrookes Hospital
Hills Road
Cambridge
CB2 2QQ
United Kingdom
Study information
| Study design | Single-centre non-randomised interventional treatment trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Non randomised study |
| Study setting(s) | Hospital |
| Study type | Treatment |
| Scientific title | Investigation of the effect of GLP-1 and left ventricular function during myocardial ischaemia |
| Study acronym | GLP-1 and left ventricular function during ischaemia |
| Study objectives | The hypothesis is that infusion of glucagon-like peptide-1 will protect the heart from ischaemia and improve left ventricular (LV) function during dobutamine stress echocardiography in patients with coronary artery disease |
| Ethics approval(s) | MREC approved, ref: 08/H0304/68 |
| Health condition(s) or problem(s) studied | Topic: Cardiovascular; Subtopic: Cardiovascular (all Subtopics); Disease: Cardiovascular |
| Intervention | In the active DSE, patients will receive an infusion of GLP-1 intravenously at 1.2 pmol/kg/min starting 30 minutes prior to the DSE and continuing for 30 minutes into recovery. In the control scan there will be no infusion. |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | Not Applicable |
| Drug / device / biological / vaccine name(s) | Glucagon-like peptide-1 |
| Primary outcome measure | Global LV function at peak stress |
| Secondary outcome measures | 1. Global LV function at 30 minutes recovery 2. Regional wall LV function at 30 minutes recovery 3. Regional wall LV function at peak stress |
| Overall study start date | 17/06/2009 |
| Completion date | 30/07/2010 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Not Specified |
| Sex | Not Specified |
| Target number of participants | Planned sample size: 30; UK sample size: 30 |
| Key inclusion criteria | Not provided at time of registration |
| Key exclusion criteria | Not provided at time of registration |
| Date of first enrolment | 17/06/2009 |
| Date of final enrolment | 30/07/2010 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
University of Cambridge
Cambridge
CB2 2QQ
United Kingdom
CB2 2QQ
United Kingdom
Sponsor information
Cambridge University Hospitals NHS Foundation Trust (UK)
Hospital/treatment centre
Hospital/treatment centre
Addenbrookes Hospital
Hills Road
Cambridge
CB2 2QQ
England
United Kingdom
| Website | http://www.cuh.org.uk/ |
|---|---|
"ROR" |
https://ror.org/04v54gj93 |
Funders
Funder type
Research council
Medical Research Council (MRC) (UK)
Government organisation / National government
Government organisation / National government
- Alternative name(s)
- Medical Research Council (United Kingdom), UK Medical Research Council, MRC
- Location
- United Kingdom
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 01/03/2012 | Yes | No | |
| Results article | results | 08/08/2015 | Yes | No |
